AIM Immunotech Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AIM Immunotech Inc.
Financing Quarterly Statistics, Q4 2022
During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.
The Hunt For Big Fish: How KDDF Is Helping Create Korean Deals
Korea Drug Development Fund CEO H. Samuel Muk talks to Scrip how the government agency has evolved to support the Korean biopharma industry’s R&D and business development activities, as well as what key new projects are underway.
A Promising Future For Oncolytic Viruses As Cancer Immunotherapies
The development of oncolytic virus therapy has gained momentum over the past decade, due to its relatively safe mode of action and potential to enhance existing treatment options. A third of cancer vaccines in development are now oncolytic viruses, which are being developed for about 40 different types of cancer. In Vivo takes a closer look at therapies in development to see what the future holds for this promising therapy.
Deal Watch: Gemini Goes Through Second Re-Invention Via Reverse Merger With Disc Medicine
Less than two year after going public by a SPAC merger, Gemini will reverse merge with hematology-focused Disc. Bristol Myers Squibb and GentiBio will join forces on Treg development for inflammatory bowel disorders.
- Contract Research, Toxicology Testing-CRO
- Contract Manufacturing Organization
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Other Names / Subsidiaries
- Hemispherx Biopharma, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.